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Altered brainstem responses to modafinil
in schizophrenia: implications for
adjunctive treatment of cognition
Michael J. Minzenberg1, Jong H. Yoon2, Steffan K. Soosman3 and Cameron S. Carter3,4
Abstract
Candidate pro-cognitive drugs for schizophrenia targeting several neurochemical systems have consistently failed to
demonstrate robust efficacy. It remains untested whether concurrent antipsychotic medications exert
pharmacodynamic interactions that mitigate pro-cognitive action in patients. We used functional MRI (fMRI) in a
randomized, double-blind, placebo-controlled within-subject crossover test of single-dose modafinil effects in 27
medicated schizophrenia patients, interrogating brainstem regions where catecholamine systems arise to innervate
the cortex, to link cellular and systems-level models of cognitive control. Modafinil effects were evaluated both within
this patient group and compared to a healthy subject group. Modafinil modulated activity in the locus coeruleus (LC)
and ventral tegmental area (VTA) in the patient group. However, compared to the healthy comparison group, these
effects were altered as a function of task demands: the control-independent drug effect on deactivation was relatively
attenuated (shallower) in the LC and exaggerated (deeper) in the VTA; in contrast, again compared to the comparison
group, the control-related drug effects on positive activation were attenuated in LC, VTA and the cortical cognitive
control network. These altered effects in the LC and VTA were significantly and specifically associated with the degree
of antagonism of alpha-2 adrenergic and dopamine-2 receptors, respectively, by concurrently prescribed
antipsychotics. These sources of evidence suggest interacting effects on catecholamine neurons of chronic
antipsychotic treatment, which respectively increase and decrease sustained neuronal activity in LC and VTA. This is
the first direct evidence in a clinical population to suggest that antipsychotic medications alter catecholamine
neuronal activity to mitigate pro-cognitive drug action on cortical circuits.
Introduction
Schizophrenia is a common, severe, high-impact dis-
order with cognitive deficits representing a critical
determinant of clinical outcome1,2. Cognitive impairment
is particularly important among processes that are highly
dependent on cortical networks operated by the pre-
frontal cortex (PFC)3,4. Presently, there is no established
treatment for cognitive impairment in schizophrenia, and
therefore, advances in this research area have the poten-
tial to alleviate a considerable global illness burden.
Two major candidate neural targets for the remediation
of PFC dysfunction in schizophrenia are the catechola-
mine systems arising from the pontine locus coeruleus
(LC) and midbrain ventral tegmental area (VTA), which
use norepinephrine (NE) and dopamine (DA) respectively
as neurotransmitters. These systems project widely
throughout the cortex, and are well-suited to modulate
widely-distributed neural networks such as those engaged
by the PFC during higher-order cognition. Indeed, there is
ample evidence in both animal models and humans that
NE and DA strongly modulate PFC neurons, PFC-
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operated networks, and PFC-dependent cognitive pro-
cesses such as working memory and cognitive control5–9.
Models of catecholamine neuronal activity suggest that
optimization of cortical networks and cognition arises
from robust catecholamine neuronal responses to task-
relevant information. These responses in turn require a
moderate level of tonic, background activity, which tends
to be a function of behavioral state5,10 (see inverted-U-
shaped curve in Fig. 1b). Computational modeling sug-
gests that modest slowing of tonic background activity of
catecholamine neurons may be ideal for enhancing their
responsiveness to task-relevant stimuli11. This can be
achieved pharmacologically with moderate inhibition of
plasma-membrane catecholamine transport, which
increases catecholamine-mediated activation of inhibitory
cell-body autoreceptors12,13 (Fig. 1a). We have previously
shown that modafinil, a low-potency inhibitor of trans-
porters for NE (NET) and DA (DAT)14,15 (reviewed in
ref. 16) modulates the LC and the cortical network sub-
serving cognitive control, in a manner consistent with this
cellular model of pro-cognitive action17. This mechanism
therefore serves as an important model for the pharma-
cological modulation of PFC-based networks to remediate
cognition in schizophrenia, and could form the basis for
modafinil effects on brain function and cognition
observed in other studies of schizophrenia18.
Despite the intense interest and resources that the sci-
entific, clinical, regulatory communities and industry have
dedicated to cognition in schizophrenia, to date numerous
pharmacological strategies (targeting a wide range of
neurochemical systems) have shown minimal or incon-
sistent efficacy in clinical trials19–24. One important and
under-addressed factor driving these results could be that
antipsychotic medications mitigate the impact of candi-
date pro-cognitive agents through pharmacodynamic
mechanisms. For example, antipsychotics exert strong
effects that decrease neuronal activity in VTA-DA neu-
rons25 while increasing tonic activity in LC-NE neu-
rons26–30. These effects would then alter the responses of
these brain areas to candidate agents that modulate
catecholamine systems. Interactions with concurrent
antipsychotics could occur regardless of the neurochem-
ical system targeted by a given pro-cognitive agent, due to
the highly interacting nature of neurotransmitter systems
in the brain, where biogenic amines mutually influence
each other as well as amino acid neurotransmission31,32.
We therefore adopted an experimental medicine
approach, using fMRI to support a mechanistic, model-
driven investigation of drug action on modulation of
large-scale neural systems that support complex cogni-
tion. We tested modafinil modulatory effects on the LC,
VTA and cortical networks during cognitive performance
in schizophrenia, integrating both cellular and systems-
level neurobiological models. We report novel evidence
that the catecholamine modulatory effects of modafinil
are observable in schizophrenia in support of cognition,
yet critically, these effects are altered in a pattern con-
sistent with the actions of concurrent antipsychotic
medications.
Subjects and methods
Subjects/overview of procedures
The study was set in the University of California—Davis
Medical Center from February 2007 to July 2010. The
ClinicalTrials.gov identifier is NCT00423943. All proce-
dures were approved by the UCD Institutional Review
Board. All subjects provided informed consent for all
Fig. 1 a Cellular model of modafinil action on LC-NE neuron,
indicating how NET inhibition (red Xs on schematic neuron in second
row) by modafinil increases NE at the cell-body α2 autoreceptor,
leading to moderately-slowed tonic discharge rate, and increased NE
release (via both enhanced task-related discharge and terminal NET
inhibition). b Hypothetical model of inverted-U curve relating control-
related catecholamine cell activity to tonic activity, and the relative
effects of NET inhibition by modafinil in healthy subjects (HC) vs.
subjects with schizophrenia (SZ). The present results suggest that
compared to HC, the SZ group exhibits relatively less control-
independent deactivation in the LC (blue), relatively greater control-
independent deactivation in the VTA (blue), and less control-related
positive activation in both LC and VTA (red). Figures modified from
Invernizzi and Garattini, 2004, and Aston-Jones and Cohen, 2005
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procedures, and received remuneration for procedures,
and the study was concluded at the end of the funding
award period. There were no changes to the methods or
outcomes after trial commencement. Subjects were all
outpatients, recruited from the community and our
research clinic at UCD, and were included if they were
aged 18–50 years, and lacked the following history: neu-
rological illness, including head injury with loss of con-
sciousness, uncorrectable visual or peripheral motor
disturbance; full-scale IQ < 70 (by Wechsler Abbreviated
Scale of Intelligence: WASI); known intolerance to mod-
afinil; active substance abuse within 6 months of study;
uncontrolled medical illness; incompatability with MRI
procedures. All patients were evaluated by structured
diagnostic interview, using the SCID-I with DSM-IV-TR
criteria, and all assigned a 295.X diagnosis. Each subject
completed a double-blind, placebo-controlled crossover
study of modafinil (single oral dose 200 mg) effects on
neural activity measured by fMRI during cognitive control
task performance. BOLD signal change measured by fMRI
during the cognitive task was the primary outcome
measure, and task performance was the secondary out-
come measure. To address concurrent medication effects
in relation to altered modafinil effects on BOLD signal
change, we also derived measures of medication load at
catecholamine autoreceptor subtypes, conferred by the
schizophrenia patients’ treatment regimens, as deter-
mined by published standard indices of in vitro catecho-
lamine receptor activity (see Supplement). We tested
these hypothesized relationships by correlating con-
current medication loads with neural responses to mod-
afinil, as an additional secondary outcome measure.
Tertiary outcome measures included subjective state
measured with the POMS, and vital signs measured with a
blood pressure cuff. While this was an unprecedented,
preliminary study, sample size was approximated based
on both preliminary results from the healthy comparison
group17 and an earlier published study of modafinil effects
on prefrontal cortical function33.
See Supplemental Methods for additional detail on the
evaluation of subjects.
Cognitive Paradigm
The Preparing to Overcome Prepotency (POP) Task17
(Supplemental Fig. 1) was presented using EPrime soft-
ware. In this task, a visual cue (Red or Green color pat-
ches, 500ms duration) in the center of the visual field
instructs a stimulus-response (S–R) mapping to the
probe, which occurs after a delay (7.5 s delay from cue
offset to probe onset). The probe is an arrow that occurs
with equal frequency pointing to the left or right, pre-
sented in the center of the visual field for 500 ms in
duration. The direction of the arrow probe is randomized
to preclude the preparation of specific motor responses in
the cue-probe delay period. The response demand is
prepotent for Green-cued trials (i.e., the correct response
is a left button-press for leftward arrows, and right for
right), and is non-prepotent for Red-cued trials (i.e., left
button-press for rightward arrows, and vice versa). The
period from probe onset to cue onset of the successive
trial is 12 s. During both cue-probe delay and probe-cue
interval, subjects are instructed to fixate visually on a
crosshair presented in the center of the visual field. Four
blocks with 20 trials each were performed, with rando-
mized order of cues, 70% of which were comprised of
prepotent (Green-cued) S–R mappings, and each block
lasting 6 min 40 s. Subjects were instructed to ‘go as fast as
you can without making mistakes.’
The POP task requires cognitive control to overcome a
prepotent stimulus-response mapping. High-control
demands (Red-cued trials) are associated with decre-
ments (costs) in response accuracy and speed, and robust
activity of the lateral and medial PFC during the pre-
paratory cue-probe delay period16.
fMRI Acquisition and Pre-processing
Event-related fMRI was conducted on a 3 tesla Siemens
Trio MRI system with a Siemens 8-channel phased array
coil. Measurement of Blood Oxygen Level-Dependent
(BOLD) contrast was conducted during single-shot, echo-
planar imaging (EPI), using a T2*-weighted sequence, and
whole-brain coverage. The parameters of the EPI sequence
were TR 2000ms, TE 30ms, flip angle 90°, FOV 220 ×
220mm, with 36 contiguous slices in the axial oblique
plane with voxel size 3.4mm isotropic. In addition, a
structural MRI was acquired for normalization of EPI
images to the template, using a Magnetization-Prepared
Rapid Acquired Gradient Echo (MP-RAGE) sequence,
with the following parameters: TR 2500ms, TE 4.82ms,
acquisition time 9:20, flip angle 7°, FOV 256 × 256mm,
with 192 slices 1 mm thick. Pre-processing and analysis of
EPI images were performed using SPM5. The first four
images (preceding onset of trial one of block one) were
discarded to allow for stabilization of the scanner signal.
The remaining images were realigned (motion-corrected)
to the first retained image in the first block, and adjusted
for acquisition time (slice timing correction). At this point,
skull-stripping was performed on both MP-RAGE images
and the single-subject T1 template from SPM. The MP-
RAGE image from each subject was co-registered to the
T1 template to determine normalization parameters,
which were then applied to each EPI image for that subject
via 6-parameter rigid-body affine transformation to stan-
dard MNI space. Images were then resliced to 2 × 2 × 2
and spatially smoothed with an 8mm, full-width-at-half-
maximum Gaussian kernel. At this point, Drug and Pla-
cebo day scans were concatenated for modeling of the
signal and inferential testing.
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Modeling and inferential testing of voxel-wise drug effects on
neural activity
Derivation of the signal proceeded with the use of the
General Linear Model. Regressors were established for
Drug_RedCues, Drug_GreenCues, Placebo_RedCues, and
Placebo_GreenCues, and analogous regressors for Probes.
We also included a nuisance regressor for errors and trials
lacking a motor response, to account for these event-
related signal changes, but did not include these in the
inferential testing, as they were too rare for reliable ana-
lysis (see task performance results). A canonical (double-
Gaussian) hemodynamic response function was con-
volved with a series of delta functions to model the BOLD
time series, with regressors placed at cue and probe onset.
We also established the temporal derivative of the HRF as
a regressor, paired with each of the experimental condi-
tion regressors, to account for temporal variation in the
latency of the event-related response. A 0.0125 Hz high-
pass filter was used, a first-order autoregressive function
to account for serial autocorrelations, and grand mean
scaling to account for global differences in signal value
across test days. After signal estimation, linear contrasts
were defined at the single-subject level (see below), and
then relevant contrast maps from individual subjects
(containing voxel-wise parameter estimates for a given
contrast) were entered into group-level analysis for
inferential testing.
The control-independent Treatment effect was tested
with the contrast defined as (Drug_RedCue+Drug_-
GreenCue) > (Placebo_RedCue+ Placebo_GreenCue).
This contrast uses all available data to estimate treatment
effects that are independent of Task Condition, i.e., cog-
nitive control demands. We hypothesized that in this
contrast, significant drug effects (relative to placebo)
would be manifest as deactivations in both the LC and the
VTA, attendant to the model of catecholamine neuro-
transmission at cell bodies, an effect well-established for
catecholamine transporter inhibitors such as stimulants
and antidepressants34. In contrast, for the control-related
treatment effect on brain activity, the contrast was
established as (Drug_RedCue minus Drug_GreenCue) >
(Placebo_RedCue minus Placebo_GreenCue). This is
analogous to a directional test of the Treatment-by-Task
Condition interaction in ANOVA terminology, and in this
contrast, we hypothesized that the Drug would serve to
positively enhance LC and VTA activity. This is because
despite a control-independent effect of Drug manifest as
deactivation, the drug should augment the positive dif-
ference in activity related to cognitive control demands
(i.e., Red Cue over Green Cue-related activity), as the
cellular model suggests that a modest decrease in tonic
firing rates should be associated with an increased phasic
(i.e., task-related) firing rate, as an expression of gain
control in neural activity5. This contrast also tested the
hypothesis that elsewhere in the cognitive control net-
work, the drug would be associated with a significantly
greater enhancement of positive control-related BOLD
signal change, again compared to placebo. All contrast
maps are depicted at a threshold of p < 0.05, with clusters
corrected to p < 0.05 by small-volume (for LC and VTA)
or the False Discovery Rate (for the cortical cognitive
control network).
Code availability
All neuroimaging data pre-processing and analyses were
conducted using SPM5 software, which is readily available
in the public domain.
See the Supplemental Methods for details of localization
of the LC, VTA and cognitive control network in EPI
images, and correlation analysis of BOLD signal change
with antipsychotic receptor-binding affinities.
Results
See Supplemental Results for task performance results
fMRI results within schizophrenia group
The SZ group showed a significant control-independent
effect of Treatment (i.e., across both cue types) in both the
locus coeruleus (Fig. 2a; Supplemental Table 5) and
ventral tegmental area (Fig. 2b; Supplemental Table 5).
No control-independent Treatment effects meeting the
FDR-corrected significance level were observed elsewhere
in the brain (data not shown). Control-related Treatment
effects (i.e., on the Red Cue minus Green Cue difference)
were also interrogated both within the LC and VTA, as
well as throughout the rest of the brain. Here, no effects
were observed that met the corrected significance level.
fMRI results comparing schizophrenia group to healthy
control group
Compared to the HC group, the SZ group showed
altered control-independent Treatment effects, with
relatively shallower (i.e., attenuated) deactivation in the
LC (Fig. 3a; Supplemental Table 5), and deeper (i.e.,
stronger) deactivation in the VTA (Fig. 3b; Supplemental
Table 5). For the control-related treatment effect, the SZ
group was impaired relative to the HC group in both the
LC and VTA (Fig. 4a,b; Supplemental Table 5). In the
cognitive control network, the control-related treatment
effect of modafinil was impaired in the SZ group in several
regions (Fig. 4c, Supplemental Table 5). These included
PFC regions in the bilateral superior/medial frontal gyrus
(primarily in supplementary motor area and pre-SMA),
right inferior frontal gyrus (in ventrolateral PFC), and
bilateral middle frontal gyrus (in premotor cortex); and
bilateral middle and posterior cingulate gyrus. More
posterior regions included temporoparietal areas such as
the right middle temporal gyrus, and bilateral inferior
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parietal lobule. Subcortical areas included the cerebellar
vermis, left hippocampus, and bilateral putamen extend-
ing into thalamus. No regions were observed that exhib-
ited a stronger control-related Treatment effect in the SZ
group compared to the HC group.
Association of catecholamine receptor actions of
concurrent medications with modafinil effects in LC and
VTA
We evaluated how the patients’ concurrent anti-
psychotic medications may relate to altered brainstem
responses to modafinil, as a function of antagonism of
catecholamine receptors that serve as autoreceptors
(Supplemental Methods).
LC effects
The α2 receptor load of the patients’ concurrent atypical
antipsychotic medications was reasonably normally dis-
tributed across the sample (skew= 1.24, kurtosis= 0.62),
as was the control-related modafinil effect on LC activity
(skew=−0.92, kurtosis= 0.65). This α2 receptor load was
strongly inversely related to control-related modafinil
effects on LC activity (r=−.60, p= 0.005; Fig. 5a). These
correlations persisted upon controlling for D2 load (rpartial
=−.57, p= 0.009) and muscarinic load (rpartial=−.58,
p= 0.007), suggesting a specific relationship between α2
receptor load and LC effects that was not accounted for by
other neurochemical actions nor the total dose of the
antipsychotic medications. Furthermore, muscarinic load
was not associated with control-related modafinil effects
on LC activity (r= .16; p= .50). These results indicate
that α2 receptor antagonism of the patients’ concurrent
antipsychotic medications was strongly and specifically
related to impaired modafinil effects on control-related
LC activity.
VTA effects
The D2 receptor load of the patients’ antipsychotic
medications was normally distributed across the sample
(skew= 0.76, kurtosis= 0.13), as was the VTA response
to modafinil (skew= 0.18, kurtosis=−0.83). This D2 load
was significantly related to modafinil effects on VTA
deactivation (r= .42, p= 0.031; Fig. 5b). There was a
modest decrement in this association when controlling for
global SAPS scores (rpartial= .33, p= 0.10). Muscarinic
load was not associated with modafinil effects on VTA
deactivation (r=−.13; p= 0.52). These results indicate
that D2 receptor antagonism of the patients’ concurrent
Fig. 2 Modafinil effects on control-independent activity in locus coeruleus and ventral tegmental area in Schizophrenia Group. Contrast
maps of SZ group for Control-independent effect of Modafinil Treatment on decreased activity in locus coeruleus (a) and ventral tegmental area (b).
Clusters depicted are small-volume-corrected to p < 0.05. Bar graph depicts mean betas (±s.d.) in statistically significant voxels for MOD (left) and PLC
(right). See text for details of data acquisition and analysis. See Supplemental Table 5 for characteristics of clusters
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Fig. 3 Modafinil effects on control-independent deactivation in schizophrenia group compared to healthy control group are shallower in
locus coeruleus and deeper in ventral tegmental area. Contrast maps of SZ group minus HC group, for Control-independent effect of Modafinil
Treatment, on activity in locus coeruleus (a) and ventral tegmental area (b). Clusters depicted are small-volume-corrected to p < 0.05. Bar graph
depicts mean betas (±s.d.) in statistically significant voxels for SZ (left) and HC (right) groups. Note that the SZ group, compared to the HC group,
shows relatively greater activity in LC, i.e., less deactivation, and relatively less activity in VTA, i.e., greater deactivation. See Supplemental Table 5 for
characteristics of clusters
Fig. 4 Modafinil effects on control-related positive activation in locus coeruleus, ventral tegmental area and neocortical cognitive control
network are impaired in schizophrenia group compared to healthy control group. Contrast maps of SZ group minus HC group, for Control-
related effect of Modafinil Treatment on activity within locus coeruleus (a), ventral tegmental area (b), and brain as a whole (c). Bar graph depicts
mean betas (±s.d.) in statistically significant voxels for SZ (left) and HC (right) groups. Note that the SZ group, compared to the HC group, shows
relatively impaired Treatment effects on control-related activity in both subcortical catecholamine brain regions as well as in various regions of the
fronto-subcortical cognitive control network. See Supplemental Table 5 for characteristics of clusters meeting corrected threshold
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medications was moderately and specifically related to
stronger deactivating effects of modafinil in the VTA.
Discussion
In this study, we provide the first available evidence that
fMRI can be used to demonstrate the modulatory effects
of a drug with pro-cognitive potential on activity in the
locus coeruleus and the ventral tegmental area, in a
cognitively-impaired clinical population during cognitive
performance. We found that modafinil administration
leads to relative deactivation in LC and VTA in schizo-
phrenia patients, consistent with predictions of control-
independent effects arising from NET and DAT inhibition
at cell bodies in these subcortical regions (Fig. 1a).
Importantly, these effects were altered compared to a
healthy control group, with two lines of evidence sug-
gesting an interaction with the concurrent antipsychotic
medications prescribed to these patients was responsible
for these altered responses. First, relative to the healthy
control group, the patients responded to modafinil with
shallower deactivation in LC and deeper deactivation in
VTA. This pattern is consistent with the underlying
effects of chronic antipsychotic medication treatment,
which lead to sustained decreases in tonic firing in the
VTA, and increases in tonic firing in the LC. Second,
these altered modafinil effects in the LC and VTA were
significantly correlated respectively with antagonism at α2
and D2 receptors (despite the relatively simple measure of
receptor load used here), These receptor subtypes serve
an important regulatory autoreceptor-mediated inhibition
of NE and DA neurons, respectively. In the patients
overall, the consequences of altered responses to mod-
afinil was that the drug was less able to positively mod-
ulate control-related increases in activity, in both these
subcortical regions and in neocortical and subcortical
terminal fields that support cognitive control (see Fig. 1b
for hypothetical model of altered modafinil effects on
catecholamine neuron activity in SZ). These findings have
significant potential implications for the prospects of
candidate drugs to normalize cortical dysfunction in
schizophrenia, to remediate impaired cognition.
Chronic treatment with either typical or atypical anti-
psychotics leads to sustained increases in firing of LC
neurons26–30. The tonic disinhibition of LC-NE neurons
may then mitigate or override the feedback inhibition of
LC-NE activity via cell-body autoreceptors, which would
be manifest as the shallower control-independent deac-
tivation in patients that we observed by fMRI. Given the
relationship of tonic to phasic LC activity5, proxied here
respectively as control-independent and control-related
BOLD signal change, this increased tonic LC activity
(unnormalized by modafinil) would impede relative
control-related increases in LC-NE activity. We have
observed just this combination of control-independent
and control-related drug effects in our patient sample. It
remains unclear which monoamine receptor(s) mediates
the antipsychotic effect on LC activity. However, we found
that the α2 antagonist load of the concurrent
Fig. 5 Relationship of modafinil effects in LC and VTA to catecholamine receptor antagonism by concurrent antipsychotic medications. a
Control-related effect of modafinil in LC is attenuated by α2 antagonism of concurrent antipsychotic medications. Scatterplot of mean betas in
control-related modafinil effect in LC, as a function of α2 receptor loads (in haloperidol equivalents) conferred by patients’ antipsychotic medications.
Subgroup (n= 21) on monotherapy with atypical antipsychotics. r=−0.60, p= 0.005. b Control-Independent effect of modafinil on deactivation in
VTA is positively related to D2 antagonism by concurrent antipsychotic medications. Scatterplot of mean betas in VTA in response to control-
independent modafinil effect (Drug minus Placebo), as a function of D2 receptor loads conferred by patients’ antipsychotic medications (n= 27). r=
−0.42, p= 0.031
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antipsychotics was strongly and specifically related to
impaired modafinil effects on control-related LC activity.
This convergent evidence suggests that antagonism of the
cell-body α2 autoreceptor leads to impaired optimization
of control-related phasic LC activity. This evidence sup-
ports the model we outlined previously, where modafinil
action to inhibit NET at LC cell bodies leads to
autoreceptor-mediated slowing of control-independent
LC activity, allowing optimized control-related phasic LC
activity to effectively modulate the cognitive control net-
work (Fig. 1b)17.
In contrast to the activating effects on the LC, chronic
antipsychotic treatment induces depolarization inactiva-
tion in VTA-DA neurons, rendering the cell-body less
able to generate action potentials (reviewed in25). The
relatively depolarized (but not discharging) state of
antipsychotic-exposed VTA-DA neurons may then render
these neurons relatively more sensitive to DAT inhibitor
effects that increase DA at cell bodies. This increased
sensitivity could also result from relatively more D2
receptors in a high-affinity state, which is induced with
chronic antipsychotic treatment and associated with the
D2 affinity of these medications
35. One of the present
findings, that the deactivating effect of modafinil on the
VTA was significantly related to the D2 load conferred by
the patients’ concurrent antipsychotic medications, sug-
gests that D2-receptor effects interact with modafinil
responses in the VTA. Exaggerated deactivation of the
VTA to modafinil could render these neurons
suboptimally-responsive to control-related excitatory
inputs, leading to the dissociation of cell-body vs. terminal
effects of DAT inhibition (see penultimate paragraph
below). This effect may also interact with underlying
pathophysiology in this system, manifest in either neu-
rochemical disturbances and/or altered responses to
cognitive demands35–39. These considerations highlight
the utility of an experimental medicine approach using
in vivo methods such as fMRI, to afford direct tests in
patient populations of model-driven predictions about the
pharmacological modulation of these systems during
cognitive processes40.
The emphasis here on cell-body effects of modafinil,
and modulation of neuronal activity in the LC and VTA,
is entirely compatible with models of catecholamine
function that emphasize post-synaptic actions in the
PFC4,6,9. Phasic activity in both VTA10 and LC neu-
rons41,42 leads to greater neurotransmitter release com-
pared to tonic activity, and optimizes throughput in active
cortical ensembles, which may be mediated by D1
6,7 or α2
9
receptors. It remains likely that modafinil exerts impor-
tant actions at NET in terminals in the PFC, probably to
amplify the beneficial effects of cell-body modulation. The
D2-mediated antipsychotic effects observed here could
also relate to actions at DA terminals in the PFC, and α2
antagonist effects also manifest directly at post-synaptic
receptors in PFC, both leading to altered descending
cortical input to the LC and VTA. Antipsychotic treat-
ment may in fact induce a state where cell-body, terminal
and post-synaptic actions are uncoupled in response to
catecholamine transport inhibition. In this scenario,
antipsychotic treatment leads to: (1) altered effects of pro-
cognitive NET/DAT inhibition on cell-body activity
(observed here), combined with (2) increased release of
residual NE and DA, resulting from both terminal auto-
receptor antagonism (by antipsychotics) plus NET and
DAT inhibition (by modafinil), but in a manner uncou-
pled to cell-body activity (and the influence of control-
related excitatory input to catecholamine neurons from
the PFC and elsewhere), and (3) direct antagonism by
antipsychotics of post-synaptic D2 and α2 receptors in the
cortex. Thus, the circuit that maintains bidirectional
influence of these subcortical neurochemical systems with
cortical networks would be disrupted, unable to respond
to a modulatory drug with pro-cognitive potential such as
modafinil.
This study is limited by a rather modest sample size, and
that the antipsychotic medication treatment was natur-
alistic and not randomized nor blinded, unlike the single
dose of modafinil. Nevertheless, the correlations of BOLD
signal change in response to modafinil exhibited specifi-
city in their relationships with monoamine receptor-
mediated effects of antipsychotics, which were predicted
based on the known neurochemical effects of both mod-
afinil and antipsychotics, and were generally not attribu-
table to overall illness severity as measured by psychotic
symptoms nor proxied by other neurochemical effects of
the antipsychotics. In addition, many of these subjects
were concurrently prescribed other psychotropic agents
(and in a few cases, non-psychiatric medications, for other
medical conditions). It remains unclear if these other
medications may have contributed to the altered neural
responses to modafinil observed here. Nonetheless, the
pattern of observed effects fit very well the predicted
pattern based on the actions of antipsychotic drugs on
these systems, and how they would be expected to interact
with modafinil. In addition, the supplemental medications
are reasonably-representative of the adjunctive treatments
that are routinely used with schizophrenia outpatients,
suggesting that the observed altered brain responses are
likely representative of those that may be found among
schizophrenia patients more generally.
In addition, the patient sample was quite characteristic
of outpatient, community-dwelling populations with
schizophrenia, in terms of demographics, symptomatol-
ogy and functional status. These observations suggest that
the present findings may have general relevance for the
future clinical management of outpatients with schizo-
phrenia, and the potential challenge of resolving
Minzenberg et al. Translational Psychiatry  (2018) 8:58 Page 8 of 10
treatment for psychotic symptoms that are the clinical
hallmark of the disorder, with the cognitive impairment,
which is not a defining feature of schizophrenia yet
remains a major determinant of functional outcome.
It is very important to emphasize that in no way do
these considerations suggest that modern antipsychotic
medications be abandoned or that their use be curtailed.
These medications are the mainstay of treatment of all
psychotic disorders, and remain the most important
advance in the history of schizophrenia treatment43. It is
nonetheless interesting to consider how an antipsychotic
agent with relatively less catecholamine antagonist activity
may mitigate these problems and serve as a better alter-
native, in combination with novel pro-cognitive agents, to
facilitate the development of new treatments for cognition
in this illness.
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